Régulier
- 246,00$
- Membre: 23124$
Vous pourriez économiser 14,76 $ en devenant membre
Providing must-have knowledge for the pharmaceutical industry and process chemists in industry, this ready reference offers solutions for saving time and money and supplying -- in a sustainable way -- valuable products. Application-oriented and well structured, each chapter presents successful strategies for the latest modern drugs, showing how to provide very fast bulk quantities of drug candidates. Throughout, the text illustrates how all the key factors are interwoven and dependent on one another in creating optimized methods for optimal products.Preface
Efavirenz®, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
CCR5 Receptor Antagonist
5a-Reductase Inhibitors -
The Finasteride Story
Rizatriptan (Maxalt®): A 5-HT1D Receptor Agonist
SERM: Selective Estrogen Receptor Modulator
HIV Integrase Inhibitor: Raltegravir
Cyclopentane-Based NK1 Receptor Antagonist
Glucokinase Activator
CB1R Inverse Agonist -
Taranabant"The book will be of great value to students looking to move into a career in process research; the enthusiasm and commitment of the authors comes over in the text, and the attention to detail and emphasis on mechanistic evaluation is a lesson to all. Academics will find much material that can be used in teaching . . . so in conclusion, this is an outstanding book which discusses the art of process research and developing process understanding." (Organic Process, Research & Development Journal, 17 December 2010)
Nobuyoshi Yasuda received his bachelor from Tokyo Institute of Technology under the direction of Professor Teruaki Mukaiyama and Professor Hisashi Takei and his mater degree from the same university under the direction of Professor Hisashi Takei. After working at Fujisawa Pharmaceutical Company, Japan as a Medicinal Chemist, he received Ph. D. from Tokyo Institute of Technology in 1987. After spend one year as a postdoctoral fellow under Professor Robert M. Williams at Colorado State University from 1988 to 1989, he joined in Process Chemistry, Merck Research Laboratories in 1990. He has over 60 publications and over 50 patents.The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.
Efavirenz®, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
CCR5 Receptor Antagonist
5a-Reductase Inhibitors -
The Finasteride Story
Rizatriptan (Maxalt®): A 5-HT1D Receptor Agonist
SERM: Selective Estrogen Receptor Modulator
HIV Integrase Inhibitor: Raltegravir
Cyclopentane-Based NK1 Receptor Antagonist
Glucokinase Activator
CB1R Inverse Agonist -
Taranabant"The book will be of great value to students looking to move into a career in process research; the enthusiasm and commitment of the authors comes over in the text, and the attention to detail and emphasis on mechanistic evaluation is a lesson to all. Academics will find much material that can be used in teaching . . . so in conclusion, this is an outstanding book which discusses the art of process research and developing process understanding." (Organic Process, Research & Development Journal, 17 December 2010)
Nobuyoshi Yasuda received his bachelor from Tokyo Institute of Technology under the direction of Professor Teruaki Mukaiyama and Professor Hisashi Takei and his mater degree from the same university under the direction of Professor Hisashi Takei. After working at Fujisawa Pharmaceutical Company, Japan as a Medicinal Chemist, he received Ph. D. from Tokyo Institute of Technology in 1987. After spend one year as a postdoctoral fellow under Professor Robert M. Williams at Colorado State University from 1988 to 1989, he joined in Process Chemistry, Merck Research Laboratories in 1990. He has over 60 publications and over 50 patents.The refinement of a chemical process to the point where it becomes both cost and time efficient can be seen as "art." In a competitive environment where pharmaceutical companies are under ever increasing pressure to bring new drugs more quickly to the market, ways need to be found to provide bulk supplies of drug candidates as quickly as possible and to design manufacturing routes, which are robust, economical and environmentally firendly. This monograph is divided into 9 chapters, each one concentrating on a single class of drug candidates of chemistry development and describing the routes explored and the optimizations made to each drug candidate, inluding the discovery of applicable new chemistry and the elucidation of reaction mechanism.
From the contents:
- Efairenz®, a Non-Nucleoside Reverse Transciptase Inhibitor (NNRTI), and a Previous Structurally Related Development Candidate
- CCR5 Receptor Antagonist
- 5α-Reductase Inhibitors – The Finsteride Story
- Rizatriptan (Maxalt®): A 5-HT1D Receptor Agonist
- SERM: Selective Estrogen Receptor Modulator
- HIV Integrase Inhibitor: Raltegravir
- Cyclopentane-Based NK1 Receptor Antagonist
- Glucokinase Activator
- CB1R Inverse Agonist – Taranabant
Catégories
Caractéristiques
-
- ISBN9783527324705
- Code produit648096
- ÉditeurWILEY, JOHN (WILEY)
- Date de publication1 novembre 2010
- FormatPapier